Translational and pharmacokinetic‐pharmacodynamic application for the clinical development of GDC‐0334, a novel TRPA1 inhibitor-Reference-Cited by-同舟云学术

Translational and pharmacokinetic‐pharmacodynamic application for the clinical development of GDC‐0334, a novel TRPA1 inhibitor

Published:2021-05-31 Issue:5 Volume:14 Page:1945-1954
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Chan Phyllis¹^ORCID,Ding Han Ting¹,Liederer Bianca M.²,Mao Jialin²,Belloni Paula³,Chen Liuxi²,Gao Simon S.⁴,Joseph Victory⁵,Yang Xiaoying⁶,Lin Joseph S.³,Mitra Mayur S.⁷,Putnam Wendy S.¹,Quartino Angelica¹^ORCID,Bauer Rebecca N.⁸,Pan Lin¹

Affiliation:

1. Department of Clinical Pharmacology Genentech, Inc South San Francisco California USA

2. Department of Drug Metabolism & Pharmacokinetics Genentech, Inc South San Francisco California USA

3. Department of Clinical Sciences Early Clinical Development Genentech, Inc South San Francisco California USA

4. Department of Clinical Imaging Genentech, Inc South San Francisco California USA

5. Department of Biomedical Imaging Genentech, Inc South San Francisco California USA

6. Department of Biostatistics Early Clinical Development Genentech, Inc South San Francisco California USA

7. Department of Toxicology Genentech, Inc South San Francisco California USA

8. Department of Biomarker Development Early Clinical Development Genentech, Inc South San Francisco California USA

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13049

Reference15 articles.

1. Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation

2. Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective

3. Pharmacokinetic/Pharmacodynamic Modeling of the PDE4 Inhibitor TAK-648 in Type 2 Diabetes: Early Translational Approaches for Human Dose Prediction

4. Transient receptor potential channels as therapeutic targets

5. α-Aryl pyrrolidine sulfonamides as TRPA1 antagonists

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An updated patent review of TRPA1 antagonists (2020 – present);Expert Opinion on Therapeutic Patents;2024-05-03

2. Using automated patch clamp electrophysiology platforms in ion channel drug discovery: an industry perspective;Expert Opinion on Drug Discovery;2024-03-13

3. Human Transient Receptor Potential Ankyrin 1 Channel: Structure, Function, and Physiology;Subcellular Biochemistry;2024

4. TRP channels in respiratory disorders;TRP Channels as Therapeutic Targets;2024

5. TRPA1 Antagonist LY3526318 Inhibits the Cinnamaldehyde‐Evoked Dermal Blood Flow Increase: Translational Proof of Pharmacology;Clinical Pharmacology & Therapeutics;2023-09-21